This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.
The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels – in the context of current issues and future trends, including those related to COVID-19 – and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.
Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Edited by Wolf Sauter, Full Professor of Law, Markets and Behavior, Vrije Universiteit Amsterdam and Coordinating Specialist Enforcement Official, Dutch Authority for Consumers and Markets (ACM), Marcel Canoy, Endowed Professor of Health Economics, Vrije Universiteit Amsterdam and Economic Adviser to Dutch Authority for Consumers and Markets (ACM) and Jotte Mulder, Antitrust attorney, Pels Rijcken, The Hague and Assistant Professor, Utrecht University, the Netherlands
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Mooney's bookstore, Den Helder, Pays-Bas
Etat : Very Good. N° de réf. du vendeur 6E3FC08E5B1DC02
Quantité disponible : 1 disponible(s)
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. N° de réf. du vendeur 94Z30OOC6S
Quantité disponible : Plus de 20 disponibles
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In English. N° de réf. du vendeur ria9781802204407_new
Quantité disponible : Plus de 20 disponibles
Vendeur : Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlande
Etat : New. 2022. Hardback. . . . . . N° de réf. du vendeur V9781802204407
Quantité disponible : Plus de 20 disponibles
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. N° de réf. du vendeur 402224993
Quantité disponible : 3 disponible(s)
Vendeur : Books Puddle, Woodside, NY, Etats-Unis
Etat : New. N° de réf. du vendeur 26395233470
Quantité disponible : 3 disponible(s)
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
HRD. Etat : New. New Book. Shipped from UK. Established seller since 2000. N° de réf. du vendeur FW-9781802204407
Quantité disponible : 15 disponible(s)
Vendeur : Rarewaves.com USA, London, LONDO, Royaume-Uni
Hardback. Etat : New. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law. N° de réf. du vendeur LU-9781802204407
Quantité disponible : 8 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Hardcover. Etat : Brand New. 1st edition. 307 pages. 9.50x6.25x1.00 inches. In Stock. N° de réf. du vendeur __1802204407
Quantité disponible : 2 disponible(s)
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels in the context of current issues and future trends, including those related to COVID-19 and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9781802204407
Quantité disponible : 1 disponible(s)